Pulmonary Cell News 6.14 April 13, 2017 | |
| |
TOP STORYThe authors showed that KRAS activates lipogenesis, and this activation results in distinct proteomic and lipid signatures. The inhibition of fatty acid synthase by cerulenin, a small molecule antibiotic, blocked cellular proliferation of KRAS-associated lung cancer cells. [Proc Natl Acad Sci USA] Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)Scientists employed lineage analysis in uninjured and chemically injured lungs to investigate the role of uroplakin3a-expressing club cells (U-CCs) as epithelial progenitors. U-CCs proliferated and generated CCs and ciliated cells in uninjured airways long-term and, like variant-CCs, after naphthalene. [Cell Rep] Full Article | Graphical Abstract The authors inhibited surfactant protein-C (SP-C) expression in human and murine alveolar epithelial cells (AECs) using lentivirus vector expressing shRNA and tested p53 and downstream changes in urokinase-type plasminogen activator (uPA)-fibrinolytic system. Inhibition of SP-C expression in AECs induced p53 and activated caspase-3, indicating AEC apoptosis. [Am J Physiol Lung Cell Mol Physiol] Abstract Scientists aimed to reveal the potential mechanism responsible for the anti-inflammatory effects of irisin on LPS-induced acute lung injury in mice and in A549 cells. The results of histopathological changes showed that irisin ameliorated the lung injury that was induced by LPS in time- and dose-dependent manner. [Biochem Biophys Res Commun] Abstract Galectin-1 Inhibition Attenuates Profibrotic Signaling in Hypoxia-Induced Pulmonary Fibrosis Researchers demonstrated that hypoxia is a physiological insult that contributes to pulmonary fibrosis and define its molecular roles in profibrotic activation of lung epithelial cells. Hypoxia increased transcription of profibrotic genes and altered the proteomic signatures of lung epithelial cells. [Cell Death Discov] Full Article LUNG CANCERSelective Targeting p53WT Lung Cancer Cells Harboring Homozygous p53 Arg72 by an Inhibitor of CypA The authors identified a novel cyclophilin A (CypA) small molecule inhibitor (HL001) that induces non-small cell lung cancer cell cycle arrest and apoptosis via restoring p53 expression. They found that HL001 stabilizes p53 through inhibiting the MDM2-mediated p53 ubiquitination. [Oncogene] Full Article Investigators report the discovery of a molecular interaction between WD repeat protein 79 (WDR79) and USP7 and showed its functional significance in linking the Mdm2-p53 pathway to the proliferation of non-small cell lung cancer cells. [Cell Death Dis] Full Article Scientists examined the role of miR-214 in the acquired resistance to erlotinib in non-small-cell lung cancer (NSCLC), and elucidated the underlying mechanisms. qRT-PCR assay detected higher miR-214 expression in the plasma of NSCLC patients with acquired epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) resistance than prior to EGFR-TKI therapy, and in the generated erlotinib-resistant HCC827 cells than in HCC827 cells. [Sci Rep] Full Article In in vitro experiments, low frequency magnetic fields (LF-MF) were found to induce cell growth arrest, cell senescence and inhibit iron metabolism of lung cancer cells. Moreover, LF-MF stabilized p53 protein via inhibiting cell iron metabolism and the stabilized p53 protein enhanced miR-34a transcription. [Sci Rep] Full Article Combined, the targeting of epidermal growth factor receptor and protein kinase C may have an additive or synergistic effect in lung cancer treatment. Investigators explored the potential utility by inhibiting these two pathways with the combination of erlotinib and chelerythrine chloride in non-small cell lung cancer cell lines. [PLoS One] Full Article | |
| |
REVIEWSMolecular Biomarkers for Lung Adenocarcinoma The identification of oncogenic driver alterations that underlie sensitivity to small inhibitors has led to growing interest in identifying additional targetable oncogenes in non-small cell lung cancer. Although the therapeutic impact of the discovery of these alterations has now been widely demonstrated, the epidemiological data associated with each of these biomarkers remain insufficiently studied. [Eur Respir J] Abstract Visit our reviews page to see a complete list of reviews in the pulmonary cell research field. | |
| |
INDUSTRY NEWSGenentech announced that the global, randomized Phase III ALEX study met its primary endpoint and showed that Alecensa® as an initial treatment significantly reduced the risk of disease worsening or death compared to crizotinib in people with anaplastic lymphoma kinase-positive advanced non-small cell lung cancer. [Genentech, Inc.] Press Release Enterprise Therapeutics Receives Funding from Cystic Fibrosis Trust Enterprise Therapeutics Ltd has won funding from the Cystic Fibrosis Trust to identify new drug mechanisms for the treatment of cystic fibrosis. [Enterprise Therapeutics Ltd] Press Release | |
| |
POLICY NEWSJoining the European Union Leads to Less Cross-Border Collaboration When the European Union expanded in the 2000s, it had a negative impact on scientific collaborations between researchers in new member countries and elsewhere, a study has found. [Nature News] Editorial U.S. Report Calls for Research Integrity Board A new report from the National Academies of Sciences, Engineering, and Medicine entitled Fostering Integrity in Research recommends that universities and scientific societies create, operate, and fund a new, independent, nongovernmental Research Integrity Advisory Board. [ScienceInsider] Editorial Billion-Dollar Boost Sought for Canadian Science The Canadian government should increase its support for fundamental science by more than a third, from Can $3.5 billion per year to Can $4.8 billion, according to a long-awaited independent review of the country’s research priorities and funding. Although Canada’s three major granting agencies and a research-support fund received a record-breaking Can $95-million boost in 2016, their funding stayed flat in the 2017 budget that the government released last month. The science review recommends increases for those three agencies, as well as a handful of other programmes, that would amount to Can $325 million per year for four years. [Nature News] Editorial
| |
EVENTSNEW 2nd Bioprocessing of Advanced Cellular Therapies Congress Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESNEW Postdoctoral Researcher – Oncology (University of Oxford) Assistant, Associate or Full Professor Position(s) – Asthma Research (University of Pennsylvania) NIH Training Grant – Pediatric Pulmonary Medicine (University of Pittsburgh) Postdoctoral Research Associate – Chronic Lung Disease (Washington University St. Louis) Faculty Position – Cancer Biology (Wake Forest School of Medicine) Assistant Professor/Postdoctoral Research Fellow – Lung Injury and Repair (University of Tennessee) Postdoctoral Opportunity – RNA and Cancer Biology (Yale University) PhD Student – Asthma Research (Karolinska Institute) Principal Scientist – Translational Development (Celgene Corporation) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pulmonary Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|